MedElevator
Войти в исследования Modern rheumatology · 2026
Transcriptomic Profiling and Drug Repurposing Identify Fostamatinib as a Candidate Therapeutic Agent for IgG4-Related Sialadenitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamamoto Motohisa, Kamekura Ryuta, Uehara Masaaki, Ichii Yuta, Takano Kenichi
Аннотация
OBJECTIVES: To identify therapeutic candidates for IgG4-related sialadenitis, a manifestation of IgG4-related disease characterized by IgG4-positive plasma cell infiltration and limited treatment options beyond glucocorticoids, using transcriptomic profiling and in silico drug repurposing.
METHODS: Submandibular gland tissues from 49 patients with IgG4-related sialadenitis and 3 controls were analyzed by RNA sequencing. Differentially expressed genes were screened against DrugBank to identify druggable targets. Candidate drugs were prioritized based on their ability to modulate disease-associated gene signatures. Molecular docking was performed to evaluate binding affinities to key targets.
RESULTS: Transcriptomic analysis revealed upregulation of immune-related pathways. DrugBank integration identified fostamatinib as a top candidate targeting multiple kinases, including SYK, BTK, and JAK3. Docking analysis demonstrated favorable binding affinity, particularly to BTK.
CONCLUSION: This integrative approach highlights fostamatinib as a promising therapeutic candidate and supports a role for the SYK-BTK axis in IgG4-RD pathogenesis, suggesting a potential alternative to glucocorticoids.
METHODS: Submandibular gland tissues from 49 patients with IgG4-related sialadenitis and 3 controls were analyzed by RNA sequencing. Differentially expressed genes were screened against DrugBank to identify druggable targets. Candidate drugs were prioritized based on their ability to modulate disease-associated gene signatures. Molecular docking was performed to evaluate binding affinities to key targets.
RESULTS: Transcriptomic analysis revealed upregulation of immune-related pathways. DrugBank integration identified fostamatinib as a top candidate targeting multiple kinases, including SYK, BTK, and JAK3. Docking analysis demonstrated favorable binding affinity, particularly to BTK.
CONCLUSION: This integrative approach highlights fostamatinib as a promising therapeutic candidate and supports a role for the SYK-BTK axis in IgG4-RD pathogenesis, suggesting a potential alternative to glucocorticoids.